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Abstract 
Background 
Among the many definitions of frailty, the frailty phenotype defined by Fried et al. is one of 
few constructs that has been repeatedly validated: first in the Cardiovascular Health Study 
(CHS) and subsequently in other large cohorts in the North America. In Europe, the Survey of 
Health, Aging and Retirement in Europe (SHARE) is a gold mine of individual, economic 
and health information that can provide insight into better understanding of frailty across 
diverse population settings. A recent adaptation of the original five CHS-frailty criteria was 
proposed to make use of SHARE data and measure frailty in the European population. To test 
the validity of the SHARE operationalized frailty phenotype, this study aims to evaluate its 
prospective association with adverse health outcomes. 
Methods 
Data are from 11,015 community-dwelling men and women aged 60+ participating in wave 1 
and 2 of the Survey of Health, Aging and Retirement in Europe, a population-based survey. 
Multivariate logistic regression analyses were used to assess the 2-year follow up effect of 
SHARE-operationalized frailty phenotype on the incidence of disability (disability-free at 
baseline) and on worsening disability and morbidity, adjusting for age, sex, income and 
baseline morbidity and disability. 
Results 
At 2-year follow up, frail individuals were at increased risk for: developing mobility (OR 
3.07, 95% CI, 1.02-9.36), IADL (OR 5.52, 95% CI, 3.76-8.10) and BADL (OR 5.13, 95% CI, 
3.53-7.44) disability; worsening mobility (OR 2.94, 95% CI, 2.19- 3.93) IADL (OR 4.43, 
95% CI, 3.19-6.15) and BADL disability (OR 4.53, 95% CI, 3.14-6.54); and worsening 
morbidity (OR 1.77, 95% CI, 1.35-2.32). These associations were significant even among the 
prefrail, but with a lower magnitude of effect. 
Conclusions 
The SHARE-operationalized frailty phenotype is significantly associated with all tested 
health outcomes independent of baseline morbidity and disability in community-dwelling 
men and women aged 60 and older living in Europe. The robustness of results validate the 
use of this phenotype in the SHARE survey for future research on frailty in Europe. 
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Background 
Associated with old age, but a unique entity, frailty is conceptualized as a state in which 
reserve function across multiple physiologic domains decline, compromising the individuals’ 
capacity to withstand stress, thereby predisposing them to poor health, functional decline, 
institutionalization and death [1-6]. Due to the complex multi-system and heterogeneous 
nature of the concept, frailty definitions abound [7]. There is no clear consensus on how to 
operationalize it [8-10] and the lack of a gold standard impedes comparisons across time, 
countries, and populations in a reliable manner. 
Among the many biological, physiological, social and psychosocial models on the possible 
causes and pathways of frailty [1,11-18], the one that has attracted considerable attention is 
the “phenotype of frailty” [1]. This concept embodies a set of signs and symptoms that is well 
aligned with geriatric syndromes, underscoring a biological origin, and reflecting a 
syndromic character in which an aggregate of multiple-system impairments that are inter-
related cause a loss of function [19-21]. As one of most widely-referenced constructs, the 
frailty phenotype is defined by the presence of three or more of the five specific measurable 
attributes: weight loss, muscle weakness, poor endurance, slow motor performance and 
reduced physical activity [1]. 
Using data from the Cardiovascular Health Study (CHS), Fried et al. operationalized the 
phenotype and confirmed its validity by showing association with 3 and 7-year incidence of 
mobility and ADL disability, independent of comorbidity among community-dwelling men 
and women aged 65 years and older [1]. Subsequently, numerous validation studies, 
including two large cohort studies carried out by Woods et al. [22] and Bandeen-Roche et al. 
[23], used the same construct with some modifications in the metric used to define each 
frailty criteria. In spite of these differences, the frailty criteria persisted in showing strong 
independent associations to poor health outcomes. By testing the criteria and their 
modifications in different populations these studies substantiate, to a greater extent, the 
generalizability of the frailty phenotype in the North America populations. 
In Europe, the large multi-country and ongoing population-based panel survey of health, 
social, and economic well-being of community dwellers aged 50 and older, entitled Survey of 
Health, Aging and Retirement in Europe (SHARE) offers an important opportunity to 
investigate the disparities of health and their determinants. With as many as 20 countries of 
the European Union participating, SHARE’s rich and detailed multidisciplinary data source is 
a promising medium to explore the relationship between frailty and its diverse environment 
in Europe. 
With this in view, using data from SHARE, Santos-Eggimann and colleagues [24] 
operationalized the Fried frailty criteria by selecting the most suitable metric available and 
applied it to the first wave of SHARE in order to quantify the burden of frailty across 
populations in Europe. Since there was considerable divergence from the metric used in the 
CHS study to define the frailty phenotype, it was necessary to test the SHARE-adapted 
metric’s prospective association with adverse outcomes in the SHARE population. 
Advancing on the work of Santos-Eggimann and colleagues, Romero-Ortuno and colleagues 
used the SHARE - operationalized phenotype and successfully demonstrated its validity in 
predicting mortality [25]. 
Testing and validating the operationalization of sound conceptual models is a necessary first 
step in assessing its reproducibility and reliability in diverse populations for cross country 
comparisons to be made possible overtime. Hence, to further the confidence in the validity of 
the SHARE metric, this paper assesses, among the survivors, the prospective association of 
the frailty criteria, as operationalized in SHARE, on incident mobility, BADL and IADL 
disability, and on worsening mobility, disability and morbidity over a 2-year follow-up in 
community dwelling women and men aged 60 and older taking part in the SHARE survey. 
Methods 
Data source and sample 
Data are derived from (SHARE, release 2.4.0) 11 countries of the European Union (Austria, 
Belgium, Denmark, France, Germany, Greece, Italy, The Netherlands, Spain, Sweden, and 
Switzerland) that participated in the 2004 and 2006 wave of SHARE. Representative samples 
of non-institutionalized population aged 50 years and older [26] were drawn from national or 
regional population based registries using simple or multistage probably sampling techniques, 
depending upon the institutional framework of each country. Data for wave1 were collected 
in 2004 and followed up in 2006 for wave2 using computer-assisted personal interview 
technique (CAPI) by trained interviewers. Mean response rates were 62%. Detailed 
description of the SHARE Methodology is documented on the SHARE website [27]. 
The study eligibility criteria was set up to include all individuals who had participated in both 
the baseline interview and consented to follow up; born prior to 1945; and reported to be 
living at home at the time of the interview in 2004. Of the 18, 105 non-institutionalized 
individuals aged 60+ who participated in 2004, 539 were reported deceased, 5,966 were lost 
to follow up, and 585 refused further participation in 2006, resulting in a study sample of 
11,015 individuals. 
Frailty definition 
Frailty was operationalized using variables in SHARE [24] that approximated those used in 
the original CHS defining the frailty phenotype construct. Muscle weakness was measured 
using a dynamometer, using the highest of 4-measurement readings (2 from each hand) of 
handgrip strength after adjusting for gender and body mass index cutoffs as specified by L. 
Fried [1]. Exhaustion criterion was met if the participant answered “yes” to the self-reported 
question: “In the last month have you had too little energy to do things you wanted to do?”. 
Unintentional weight loss was operationalized using 2 questions in SHARE: 1) “What has 
your appetite been like?”, and/or 2) “So have you been eating more or less?”. Participants 
scored positive for the criterion if they answered either “Diminution in desire for food” in 
response to the first question, or “Less” in response to the second question. Slowness was 
operationalized using two questions: “Because of health problems, do you have difficulty 
walking 100 m, or climbing one flight of stairs without resting?”. Criterion was met if 
participants answered positive to either of the two questions. Low physical activity was 
operationalized using the question “How often do you engage in activities that require a low 
or moderate level of energy such as gardening, cleaning the car or going for a walk?”. 
Participants scored positive for the criterion if responded “One to three times a month, hardly 
ever, or never”. Subjects were considered frail if they met three or more of these criteria; 
prefrail if they fulfilled one or two criteria; and not frail if they met none. 
Outcome measures 
Seven outcomes were examined to assess the robustness of the SHARE-operationalized 
frailty criteria in predicting adverse health in the SHARE sample. A 2-year incidence and a 2-
year propensity for “worsening” were computed for each of 3 dimensions of functional 
disability (mobility, IADL and BADL) as well as a 2-year worsening of morbidity. 
Functional disability 
Mobility disability was defined by self-report of difficulty in any one of the 8 upper and lower 
extremity mobility function tasks on the Rosow - Breslau scale [28]: sitting for 2 hrs; getting 
up from a chair; climbing several flights of stairs without resting; climbing 1 flight of stairs 
without resting; stooping or kneeling; reaching or extending arms above shoulder; 
pulling/pushing large objects, and lifting objects of 5 kg. IADL disability was defined by self-
report of difficulty in any one of the 7 IADL tasks on the Lawton-Brody scale [29]: using a 
map; preparing a hot meal; shopping for groceries; using a telephone; taking medications; 
doing work around the house; and managing money and paying bills. BADL disability was 
defined by self-report of difficulty in any one of the 5 BADL tasks on the Katz ADL scale 
[30]: dressing; bathing; getting in and out of bed; toileting; and eating and/or cutting up food. 
In each of these three dimensions, participants were asked: “Please tell me whether you have 
any difficulty doing each of the everyday activities on the card?”. Difficulties that were 
anticipated to last less than 3 months were excluded. 
Incident mobility, IADL and BADL disability at 2-year follow was defined as the 
development of any “new” reported difficulty observed over the 2 year period, in either of the 
3 respective functional disabilities, and computed among only those subjects free of the 
specific type of disability at baseline. Worsening of mobility, IADL and BADL disability at 2-
year follow was defined as any increase, with respect to baseline, in one or more number of 
reported difficulties in mobility, IADL, and/or BADL among subjects not already disabled at 
baseline in all the tasks of the respective functioning domains. It was calculated by taking the 
difference between the numbers of difficulties reported at follow-up (2006) and those 
reported at baseline. It was coded “0” if no change or improvement, and “1” if an increase 
was observed in the number of difficulties within each specific domain of functional 
disability. 
Morbidity 
Morbidity was defined according to the chronic disease list formulated by Fried and 
colleagues in the Cardiovascular Health Study [1]. The following 7 self-reported chronic 
diseases were selected and evaluated: 1) myocardial infarction, congestive heart failure, 
angina, peripheral vascular disease; 2) stroke; 3) HBP or hypertension; 4) diabetes mellitus; 
5) chronic obstructive pulmonary disease; 6) rheumatoid arthritis, and 7) cancer. As 
participants could answer to more than one concurrent condition, a total count was calculated 
by summing up the frequency reported by each individual at baseline. Worsening morbidity 
at 2-year follow up was defined as an increase with respect to baseline, in one or more 
number of chronic conditions observed among individuals who did not already accumulate all 
7 diagnoses. It was coded “0” if no change or improvements were observed, and “1” if an 
increase (difference between follow up and baseline count of > = 1) in the number of chronic 
conditions were observed. 
Control variables 
Sex, age (in years), and income (defined by the purchasing power of parity (PPP) household 
income adjusted for family size transformed to a logarithmic scale) were considered as 
potential confounders. Although education was considered, it was not retained due to its high 
correlation with income. Baseline morbidity was also considered as a control variable, and 
thus was categorized into 3 groups: no chronic condition; 1 chronic condition, and 2+ chronic 
conditions (multi-morbidity). 
Statistical analysis 
Using STATA statistical software program version 11, all statistical analyses were weighted 
to account for the individual country’s complex sampling schemes. Four primary sampling 
units were removed due to the inability to compute variance. Weighted proportions were used 
to describe baseline characteristics of the sample population and chi-square tests were 
performed to assess differences between the sexes. Further, bivariate analyses were carried 
out to assess the relationship between frailty and the 7 outcomes using chi-square tests of 
independence. Finally, multivariate logistic regression analyses were used to assess the effect 
of the SHARE-operationalized frailty phenotype on the incidence and worsening of 
functional capacity as well as on worsening of morbidity at 2-year follow up. 
Two multivariate models were computed for each of the 3 incidence outcomes (incident 
mobility, IADL and BADL disability) to test their independent association with frailty over a 
2-year follow up. The first model adjusted for demographic variables of age and sex; the 
second model further adjusted for baseline morbidity. Two multivariate models were also 
computed for each of the 3 “worsening” outcomes (worsening mobility, IADL and BADL 
disability). The first model adjusted for age, sex and disability-specific domain at baseline; 
the second model further adjusted for income and baseline morbidity. Finally, 2 additional 
multivariate models were computed to assess the effect of frailty on worsening morbidity. 
The first model adjusted for age, sex and baseline morbidity; the second fully adjusted model 
also included income status. 
Results 
Table 1 shows the baseline burden of frailty, functional disability and morbidity by sex in 
11,015 community dwelling men and women aged 60 years and older living in selected 
European countries. Mean age was 70 years for men and 71 years for women. The SHARE-
operationalized frailty phenotype was assessed in 10,237 participants and classified 46.0 % as 
non-frail, 41.1% as pre-frail, and 12.9% as frail. The sex–specific prevalence showed women 
to be almost twice as likely to be frail (16.4% vs. 8.6%), but only moderately more likely to 
be pre-frail (43.4% vs. 38.1%) than men. Women also self-reported to be more functionally 
dependent and morbid than men – as measured by mobility (67.8% vs. 47.5%), IADL (24.8% 
vs. 12.9%), BADL (15.0% vs. 10.2%) and multi-morbidity (32.6% vs. 28.1%). 
Table 1 Wave 1 Population baseline characteristics (weighted proportions) 
Variable Wave 1 ALL Male Female Chi2 
Outcome % % % P Value 
(weighted prop) (weighted prop) (weighted prop) 
Frailty Not frail 46.0 53.2 40.2 0.000 
 Pre-frail 41.1 38.1 43.4  
 Frail 12.9 8.6 16.4  
Age 60-64 26.4 28.8 24.5 0.000 
 65-69 23.9 26.2 22.2  
 70-74 19.5 19.9 19.2  
 75-79 15.0 13.8 15.8  
 80-84 10.8 8.2 12.8  
 85+ 4.1 3.1 5.6  
Functional status Mobility (1+) 59.0 47.5 67.8 0.000 
 BADL (1+) 12.9 10.2 15.0 0.000 
 IADL (1+) 19.6 12.9 24.8 0.000 
Morbidity Morbidity (1) 37.0 37.0 37.0 0.000 
 Comorbidity (2+) 30.6 28.1 32.6  
Table 2a shows the overall 2-year incidence of mobility (34.5%), IADL (14.8%) and BADL 
(8.8%) disability among the SHARE sample. The unadjusted risk of functional disability was 
greatest among frail, and to a lesser extent pre-frail compared to non-frail individuals. Frail 
individuals had more than 7-fold risk of developing BADLs disability; more than a 5-fold 
risk of developing IADL disability, and only a 2.5 fold risk of developing mobility disability 
compared to non-frail individuals. 
  
Table 2 Bivariate relationship between frailty in 2004 and outcomes in 2006 
Wave 2 (2006) Overall Non-frail Pre-frail Frail Chi2 
a) INCIDENCE1 % % % % p 
Mobility 34.5 29.3 43.1 70.5 0.000 
IADL 14.8 7.9 18.5 45.3 0.000 
BADL 8.8 4.4 9.6 31.6 0.000 
b) WORSENING2      
Mobility 35.6 28.9 39.0 49.7 0.000 
IADL 16.4 7.9 19.0 38.9 0.000 
BADL 10.5 19.0 10.9 30.9 0.000 
Morbidity 26.3 10.9 26.8 31.8 0.003 
1
 Limited to individuals with no prevalent disability at baseline. 
2
 Limited to individuals not at the maximum level of disability or morbidity at baseline. 
Table 2b shows that among individuals who were not already disabled in all tasks at baseline, 
the 2-year unadjusted propensity for worsening was consistently higher among frail than pre-
frail individuals for mobility (49.7% and 39.0%), IADL (38.9 % and 19.0%) and BADL (30.9 
% and 10.9 %) disability, respectively. In contrast, the likelihood of worsening morbidity 
among individuals who did not report all 7 diagnoses at baseline only slightly declined across 
the frailty gradient: 31.8 % for frail, 26.8 % for pre-frail, and 24.3 % for non-frail individuals. 
Table 3a shows frailty to be independently associated with an increased incident mobility 
(OR 3.07), IADL (OR 5.52) and BADL (OR 5.13) disability. The pre-frail category was also 
statistically significant, but with a smaller magnitude of effect. Table 3b shows that over a 2-
year follow-up period, frailty was independently associated with increased odds of worsening 
disability (mobility, IADL and BADL) and of worsening morbidity, after fully adjusting for 
potential confounders. Frail individuals were around twice as likely as pre-frail individuals to 
worsen on all three functional disabilities. In contrast, the strength of association between 
frailty and worsening morbidity was weaker for both frail (OR 1.77) and pre-frail (OR 1.30) 
individuals, but nonetheless significant. 
  
Table 3 Multivariate relationship between frailty in 2004 and outcomes in 2006 
   Pre frail Frail 
a)INCIDENCE1 Control Variables n OR CI OR CI 
Mobilty a 4813 1.59 1.31-1.92 4.10 1.42-11.84 
b 4795 1.47 1.21-1.80 3.07 1.02-9.26 
IADL a 8531 2.14 1.73-2.64 6.47 4.49-9.34 
b 8495 1.98 1.60-2.46 5.52 3.76-8.10 
BADL a 9217 1.85 1.41-2.42 6.47 4.56-9.19 
b 9176 1.65 1.25-2.17 5.13 3.53-7.44 
b)WORSENING2 
Mobility c 10138 1.63 1.41-1.87 3.18 2.40-4.22 
d 10094 1.55 1.35-1.78 2.94 2.19-3.93 
IADL e 10177 2.27 1.86-2.77 5.11 3.75-6.99 
f 10133 2.11 1.72-2.60 4.43 3.19-6.15 
BADL g 10187 2.14 1.66-2.77 5.59 3.94-7.96 
h 10143 1.91 1.47-2.49 4.53 3.14-6.54 
Chronic Conditions i 10197 1.33 1.14-1.55 1.88 1.45-2.45 
j 10156 1.3 1.12-1.52 1.77 1.35-2.32 
*p values <0.05 significant. 
aAge and sex. 
bAge, sex, income and morbility at baseline. 
cAge, sex, baseline mobility. 
dAge, sex, baseline mobility, income and baseline morbidity. 
eAge, sex, baseline IADL. 
fAge, sex, baseline IADL, income and baseline morbidity. 
gAge, sex, baseline IADL. 
hAge, sex, baseline IADL, income and baseline morbidity. 
iAge, sex, baseline morbidity. 
jAge, sex, baseline morbidity and income. 
1Limited to individuals with no prevalent disability at baseline. 
2Limited to individuals not at the maximum level of disability or morbidity at baseline. 
Discussion 
Using pooled data from across 11 European countries, the SHARE-operationalized frailty 
phenotype showed strong and significant prospective association with functional decline and 
morbidity in community-dwelling men and women aged 60 and older living in Europe. The 
findings indicate that even after adjusting for age, sex, income and baseline disability or 
morbidity, frailty persisted to be independently associated with developing mobility, IADL 
and BADL disability over a 2-year follow up. The SHARE-operationalized frailty phenotype 
was also significantly associated with worsening mobility, IADL respectively BADL 
disability, and chronic diseases independent of age, sex, income, and baseline disability and 
morbidity over a 2-year follow up. Moreover, the risk of functional decline and morbidity 
was present even among the pre-frail, but with a slightly lower magnitude of effect. This is 
consistent with the empirical evidence that the risk of disability and/or morbidity for those 
presenting with 3 or more frailty components is much higher than when 1 or 2 components 
are presented, and still greater than when no criteria is present. These results suggest that the 
metric used in SHARE to operationalize the frailty phenotype construct, as described in the 
original CHS by Fried and colleagues, is robust in identifying a subgroup of vulnerable older 
populations at risk for developing adverse outcomes. 
The results presented here are in line with previous studies validating the frailty phenotype 
for a range of adverse outcomes [22,23,31-36]. Data from the Cardiovascular Health Study 
(CHS) showed frailty and prefrailty to be independently associated with worsening mobility 
and ADL disability [1]. Similarly data on women aged 65–79 from the WHIOS indicated 
baseline frailty to independently predict ADL disability for frail and pre-frail individuals after 
adjustments for socio-demographic, disability and co-morbid conditions [22]. Data from 
WHASI & II found frailty to be significantly associated with a 3-year incidence of IADL and 
ADL disability among frail and pre-frail individuals after adjustments [23]. The findings of 
this study also concur with European studies that have explored frailty in its broader sense in 
relation to disability, morbidity, and mortality [25,37-40]. The 3 French City Study, for 
example, found frailty to be significantly associated with a 4-year incidence of disability in 
ADL and IADL after adjustments [37]. 
While the strength of associations concur, the magnitude of the associations differ from study 
to study – inevitably due to study design, sample size, study populations’ health 
characteristics at baseline and specific conditions that define the sample population 
parameters such as inclusion and exclusion criteria, and particular to this study, the specific 
metrics used to operationalize the frailty definition. For example, in comparison to studies 
mentioned above, the SHARE population reported higher baseline burden of frailty, disability 
and morbidity; its eligibility criteria did not exclude cognitively impaired or terminally ill 
subjects; its sample was composed of both men and women, and the follow up time was 2 
years. However, it also shared some similarities with the studies above, such as: a large 
sample size of community dwelling older adults aged 60 and older; a prospective follow up 
and use of the widely accepted frailty phenotype construct proposed by Fried and colleagues. 
In spite of similarities and differences in study scope, design, and population characteristics, 
the heterogeneity in the prevalence of frailty remains largely a function of the 
operationalization and assessment of each criteria that defines the phenotype, which is mostly 
likely to differ from survey-to-survey due to the difference in its conceptualization, language 
formulation and measurement [18,37,40-46]. For example, the SHARE operationalization of 
“weakness” as measured by grip strength differed from that in the InChianti study conducted 
in Italy [40] and the Toledo Study on Health and Aging study conducted in Spain [47] in that 
both of these studies used their own lowest quintile cut-offs for their underlying population, 
adjusted for sex and BMI, compared to the sex and BMI specific cut points used in the 
original CHS population set by Fried [1]. In another instance, the absence of available data on 
grip strength prompted the use of a self-reported question on the difficulty in rising from a 
chair as proxy measure for the weakness criterion [37,38]. These discrepancies may explain 
some of the observed differences in frailty prevalence found in surveys conducted in Italy 
(8.8%) [40], Spain (8.4%) [47], and France (7%) [37]. Furthermore, in a German cohort, 
Saum and colleagues demonstrated a lower overall prevalence of frailty when using 
population or country specific lowest quintiles (6.5%) compared to population-independent 
cutoffs (8.9%) [48]. To reduce the heterogeneity in reporting frailty, standardization of cut 
points for the phenotype criteria may be the best viable option for making comparisons across 
culturally, economically, and socially diverse populations such as those found in SHARE 
countries more meaningful, especially since the association with adverse health outcomes has 
been validated in many countries. 
This study found an association between frailty and worsening of morbidity, as measured by 
the deterioration in the number of select chronic conditions with respect to baseline. While a 
few researchers have used “worsening” as a metric to better understand the dynamic 
relationship between frailty and disability, it has been largely in relation to functional status 
[39]. SHARE data showed that while the odds ratio for worsening of morbidity was smaller 
than that for functional disability, it was not negligible. Moreover it showed significant 
values for prefrail individuals with slightly reduced strength of association. Although the 
odds ratios for the incidence and worsening models are of similar magnitude, the confidence 
intervals of the point estimates for worsening models are more narrow than that for incidence 
models, revealing more precise estimates – which may be due to the use of a larger analytical 
sample than one limited to a subset of those free of disability at baseline. Under resource and 
sample size constraints, a more dynamic metric such as “worsening” functional disability and 
worsening morbidity might serve to be more efficient. 
This data further delineates the significant difference between frailty and prefrailty. In 
addition to the non-negligible difference in magnitude between frailty entities across all 
adverse outcomes, the observed data suggests presence of a nonlinear relationship - arguing 
for examining frailty on a continuous scale to better explore its dynamic and interdependent 
properties. 
The major strength of this study is first, the reference to the widely adopted frailty phenotype, 
a construct that has a sound theoretical basis showing good content, construct, concurrent and 
predictive validity across diverse populations in both clinical and community settings [34,41]. 
Second, while the variables selected in SHARE depart from the original frailty criteria 
operationalized in the CHS study, this study attempted to mirror as many ‘original’ 
definitions in order to ensure valid comparisons as well as minimize any potential differential 
misclassification of outcome status. Three examples are highlighted: the use of the same 
chronic condition list, the incorporation of all 15 functional status items to assess disability, 
and the use of the same BMI and gender specific cut points to measure grip strength, all of 
which were established as per Fried et al. in the original CHS study. Third, the participation 
of 2 waves has lent itself in creating a longitudinal dimension allowing for a prospective 
analysis to be possible. Highly significant odds ratios have been found in spite of a relatively 
short 2-year follow up interval. Fourth, the risk of incident and worsening of functional status 
and morbidity is present even among the prefrail, after adjustments. Results suggest a 
possible gradient effect of frailty on adverse outcomes where changes in as little as 1 or 2 
frailty criteria can impact on destabilizing a carefully balanced homeostatic physiological 
state into a vulnerable one. Fifth, the study’s large and diverse population-based sample 
covering 11 European countries of wide economic, social and cultural heterogeneity ensures 
greater generalizability to the community-dwelling Europeans aged 60 + as well as greater 
certainty around the point estimates. Lastly, this study includes a new metric: “worsening” of 
morbidity. “Worsening of morbidity”, as an alternative to “incidence of morbidity”, is a 
useful outcome to consider for both prevention and treatment strategies in aging population 
where chronic diseases dominate the health burden. 
However a number of limitations must be made note. First, this study reports a substantial 
proportion of attrition. This is not an uncommon finding in large population-based, multi-
country, prospective studies. The analyses of baseline characteristics of the untapped data 
(lost to follow-up, refusals, deaths) reveal that this group tended to be younger (65 vs. 70), 
while sex status was non-differential. This group was only slightly more prefrail or frail 
(49%) compared to those in the analytical sample (45%). Attrition may potentially lead to a 
selection bias that might have spuriously resulted in a “healthy aging” effect. However, due 
to small differences, it is unlikely to compromise the interpretation of the results. Second, 
while the definition of morbidity used in this study was directly adopted from the CHS to 
show alignment and comparability with Fried et al., the measure is somewhat limited in the 
number and type of chronic diseases that it contains. For example, it omits prevalent 
conditions encountered in older persons such as dementia, degenerative arthritis, and mental 
health conditions. In contrast, this study used broad and rather non-specific criteria defining 
mobility disability consistent with other studies examining the relationship between frailty 
and disability [1,37,38]. The incidence of mobility disability among the frail, prefrail and 
non-frail groups in SHARE demonstrated to be of similar magnitude across the frailty 
gradient of that found in 3 City French study: frail (70.5% vs 68%), prefrail (43% vs 55%) 
and non frail (29% vs 45%) [37]. And finally, inherent to all survey data is the reliance on 
“self-reported” information which is limited by its inability for independent verification. Self-
reported data pose differential misclassification bias by sex, country or health status, and 
must be taken into account when interpreting results. In general, caution must be taken when 
making comparisons across countries, in that the variability in time, place and people will 
always exist. 
Conclusions 
The SHARE-operationalized frailty phenotype has established good construct validity by 
showing significant association with adverse outcomes, independent of baseline disability 
and comorbidity in the European population aged 60 and older. These findings provide fertile 
ground for investigating more complex interactions of biological, environmental and social 
circumstances that impact on heath trajectories, and shape the heterogeneity of frailty in 
aging populations. SHARE, with its wide-scope and detail prospective data on individual, 
economic, social, and environmental and health characteristics, is the ideal medium to further 
epidemiological research on frailty and health in Europe. 
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